<div id="readability-page-1"><div> By Jason Chau <pre></pre> Shares of Daiichi Sankyo tumbled after the Japanese drugmaker delayed the release of its earnings results. Daiichi Sankyo's stock declined nearly 11% to 2,497.50 yen, equivalent to $15.64, in Friday morning's trading session in Tokyo, marking its steepest intraday decline since August 2024. The pharmaceutical company said it will report the results for the fiscal year ended March 2026 on May 11, instead of the originally scheduled April 27. It attributed the delay to a review of its supply plans for its oncology portfolio and development pipeline, and further deliberations to estimate the loss provisions related to contract manufacturing. Daiichi Sankyo said it would also release its five-year business plan for 2026-2030 on May 11, brought forward from May 19. The delay in the earnings release comes amid rapid changes in the drugmaker's business environment as it pivots toward innovative drug discovery, particularly in the field of oncology. Earlier this month, it agreed to sell its over-the-counter drug business to Japanese beverage giant Suntory Holdings for about $1.55 billion. Daiichi Sankyo shares are down nearly 26% so far this year. <pre></pre> Write to Jason Chau at jason.chau@wsj.com <pre></pre> (END) Dow Jones Newswires April 24, 2026 01:03 ET (05:03 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

4568

第一三共株式會社(ADR)

第一三共株式會社 (ADR) 的股價下跌近 11%，至 2,497.50 日元，此前該公司因審查其腫瘤學產品組合和合同製造條款，將截至 2026 年 3 月的財報發佈推遲至 5 月 11 日。該公司還計劃在同一天發佈其 2026-2030 年的五年商業計劃。此次推遲發生在第一三共轉向創新藥物研發之際，該公司最近以 15.5 億美元將其非處方藥業務出售給了三得利控股。今年該股價已下跌近 26%

Shares of Japanese Drugmaker Daiichi Sankyo Tumble on Delay in Earnings

日本製藥公司第一三共株式會社 (ADR) 的股價因推遲公佈收益而下跌